Br J Psychiatry. 1993 Aug;163:150-4. doi: 10.1192/bjp.163.2.150.
In order to assess the safety and some efficacy aspects of clozapine under UK conditions, 54 in-patients with severe treatment-resistant schizophrenic disorders were evaluated using several scales before and during treatment. Of the 54 evaluated, 26 completed the 26-week study. Of these patients, 20 showed improvement in psychopathology, often to a marked degree, involving both positive and negative symptoms. Some oral-facial extrapyramidal side-effects decreased as well. Two patients developed neutropenia, but recovered on discontinuation of clozapine. The most frequent adverse event was hypersalivation, and five patients suffered from seizures. It is concluded that clozapine is worth considering for the treatment of severe treatment-resistant patients in the UK.
为评估在英国条件下氯氮平的安全性及某些疗效方面，对54例患有严重难治性精神分裂症障碍的住院患者在治疗前和治疗期间使用多种量表进行了评估。在评估的54例患者中，26例完成了为期26周的研究。在这些患者中，20例在精神病理学方面有改善，通常程度显著，涉及阳性和阴性症状。一些口腔面部锥体外系副作用也有所减少。2例患者出现中性粒细胞减少，但在停用氯氮平后恢复。最常见的不良事件是流涎过多，5例患者发生癫痫发作。得出的结论是，在英国，氯氮平值得考虑用于治疗严重难治性患者。
